[Molecular diagnosis of lung cancer in association with treatment of choice]
Related Experiment Video
Updated: May 16, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Yasushi Yatabe1, Noriko Shibata
1Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya 464-8681, Japan. yyatabe@aichi-cc.jp
Abstract:
Recent advances in lung cancer research have enabled significant progress in our understanding of the molecular pathogenesis and treatment for lung cancer. For example, EGFR tyrosine kinase inhibitors have been developed, and a subset of patients show marked therapeutic responses to this treatment. Subsequently, this super-response was revealed to be associated with an EGFR mutation that was identified in 2005. Currently, EGFR tyrosine kinase inhibitors are available for first-line treatments of patients with advanced non-small-cell lung cancer when the tumor is positive for an EGFR mutation. More recently, similar marked responses to an ALK inhibitor in patients with ALK fusion lung cancers were demonstrated. In this article, we review such recent advances in lung cancer, focusing on EGFR mutation and ALK fusion..
Insights
Recent lung cancer research highlights targeted therapies. Epidermal growth factor receptor (EGFR) inhibitors and anaplastic lymphoma kinase (ALK) inhibitors show significant patient responses, revolutionizing non-small cell lung cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Lung cancer research has advanced significantly, improving understanding of its molecular basis and treatment strategies.
- Targeted therapies, such as Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors, have shown remarkable efficacy in specific patient subsets.
- The identification of EGFR mutations in 2005 correlated with positive responses to these inhibitors.
Purpose of the Study:
- To review recent breakthroughs in lung cancer research.
- To focus on the molecular mechanisms and therapeutic implications of EGFR mutations and Anaplastic Lymphoma Kinase (ALK) fusions.
- To highlight the clinical application of targeted therapies in non-small cell lung cancer (NSCLC).
Main Methods:
- Review of recent scientific literature and clinical trial data on lung cancer.
- Analysis of molecular alterations, specifically EGFR mutations and ALK fusions.
- Examination of therapeutic responses to targeted inhibitors.
Main Results:
- EGFR tyrosine kinase inhibitors are now first-line treatments for advanced non-small cell lung cancer with EGFR mutations.
- Anaplastic Lymphoma Kinase (ALK) inhibitors have demonstrated significant therapeutic responses in patients with ALK fusion-positive lung cancers.
- These targeted therapies represent a paradigm shift in personalized lung cancer treatment.
Conclusions:
- Advances in understanding molecular drivers like EGFR mutations and ALK fusions have led to highly effective targeted therapies.
- Personalized medicine approaches are transforming the treatment landscape for non-small cell lung cancer.
- Continued research into molecular pathogenesis promises further improvements in lung cancer outcomes.
